Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is trading at $5.42, about ₹519 at today's USD/INR rate, as of 28 Sep 2026, 3:49 PM ET, up 5.15% today. Indian residents can buy Aclaris Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$5.03
Today's high
$5.45
52 week low
$1.74
52 week high
$6.60
ACRS opened at $5.07, closed previously at $5.15, and has traded between $1.74 and $6.60 over the past 52 weeks.
About
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Key statistics
Avg. volume
1.97M
Market cap
$756.28M
P/E Ratio
-9.34
Price-to-sales ratio
92.02
Enterprise value
$737.11M
Free cash flow yield
-8.22%
Debt-to-equity ratio
0.00
Return on equity
-61.65%
ROIC
-56.99%
Beta
0.80
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$7.83M
Earnings per share
-$0.53
Free cash flow
-$47.11M
Net profit margin
-921.50%
Gross margin
95.61%
EBITDA
-$64.47M
Revenue growth
-58.19%
Similar securities
This is not an investment recommendation
How to buy Aclaris Therapeutics from India
Indian residents can buy Aclaris Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Aclaris Therapeutics and place an order
Find Aclaris Therapeutics by name or by its ticker, ACRS, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Aclaris Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Aclaris Therapeutics position in USD and INR. Aclaris Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Aclaris Therapeutics from India
Trading and taxes when buying Aclaris Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneAclaris Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Aclaris Therapeutics stock?
Yes. Aclaris Therapeutics (ACRS) has been listed on NASDAQ since 2015, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Aclaris Therapeutics share cost in rupees?
One Aclaris Therapeutics share is $5.42 — about ₹519 at a USD/INR rate of 95.93 on 27 Sep 2026. Both the Aclaris Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Aclaris Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Aclaris Therapeutics?
Yes. One Aclaris Therapeutics share is $5.42, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Aclaris Therapeutics.
How are gains on Aclaris Therapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Aclaris Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Aclaris Therapeutics pay a dividend?
No. Aclaris Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Aclaris Therapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Aclaris Therapeutics shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Aclaris Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Aclaris Therapeutics holding, its cost and its closing value.
How do I sell Aclaris Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.